Progenics Pharmaceuticals PGNX
-
FDA Response To Progenics' Supplemental NDA Application Looms
By Brian L. Wilson : Progenics ( PGNX ) is a New York-based pharmaceutical company that is developing a drug called RELISTOR (methylnaltrexone bromide) for the specific …
-
Dendreon Could Dive If Sipuleucel-T Fails
By ValueMax : Dendreon ( DNDN ) currently has one FDA approved drug on the market. Provenge is a prostate cancer vaccine treatment manufactured by Dendreon and so far its run in the market has been a disappointing one. The fact that Provenge costs $93,000 for treatment over the course of one month
-
Competition Will Drive Dendreon's Stock Down
By Ry Frank : A renewed area of focus for many pharmaceutical and biotechnology companies is anti-cancer drugs, but, unlike the past, these drugs target smaller groups of patients for specialized treatment as well as larger groups suffering from more general forms of cancer. Unfortunately, these ...
-
4 Biotech Stocks To Consider Beyond Dendreon
By Mel Daris : Dendreon ( DNDN ) is a biotechnology company that focuses on developing cures for cancer through new and previously unheard of treatments. Dendreon hopes to find more treatment options for cancer patients to reduce the stress caused on the body by current chemotherapy and radiation
-
9 Healthcare Stocks With Major Catalysts Due in April
By Spencer Knight : After a very busy month of March, April will not be any easier for the FDA. There will be seven events in April that will involve five small cap biotech companies as well as four large cap healthcare firms. Per the usual, small cap biotech stocks are made or broken when FDA ...
-
Bio Tech Stocks With Huge Upside Or Downside Potential In April
By StockPandit : 2012 is so far the best year for the Biotechnology and Drugs industry. So many stocks surged in the last three months based on clinical trial results, U.S. Food and Drug Administration (FDA) approval, FDA Advisory Committee's recommendation, European commission approval, ...
-
What's It Going To Take To Get Salix Cheap?
By Stephen Simpson : For the most part, a company actually missing estimates on an operating basis and significantly increasing estimated expenses for the next year is enough to drive the stock down. Salix Pharmaceuticals ( SLXP ) is not an ordinary stock, though, and investors seem happy to look
-
Premarket gainers: [[CSIQ]] +27%. [[ PGNX ]] +26%. [[AIS]] +17%. [[SLXP]] +11%. [[S]] +7%. [[CLWR]] +7%. [[JEF]] +6%. [[ALU]] +6%. [[NOK]] +5%. [[DB]] +5%. [[RIO]] +5%. [[MT]] +4%. [[STD]] +4%. ...
Premarket gainers: CSIQ +27% . PGNX +26% . AIS +17% . SLXP +11% . S +7% . CLWR +7% . JEF +6% . ALU +6% . NOK +5% . DB +5% . RIO +5% . MT +4 …
-
Salix Pharmaceuticals (SLXP) and Progenics ( PGNX ) report "positive" highly statistically significant results of the Phase 3 of oral methylnaltrexone for the treatment of opioid-induced constipation ...
Salix Pharmaceuticals ( SLXP ) and Progenics ( PGNX ) report "positive" highly statistically significant results ..... constipation in subjects with chronic, non-cancer pain. SLXP +11% , PGNX +18.8% premarket. ( PR ) Post your comment!
-
20 Healthcare Stocks Undervalued By Levered Free Cash Flow
By Kapitall : In the never-ending search for potentially undervalued stocks, one indicator is the ratio levered free cash flow/enterprise value. Companies with higher ratios appear more undervalued relative to their levered free cash flows. Levered free cash flow is the free cash flow after ...